Model-informed AUC-guided monitoring of enteric-coated mycophenolate sodium: population pharmacokinetics and clinical transferability
Abstract
Delayed, variable absorption and enterohepatic recirculation complicate estimation of mycophenolic acid (MPA) exposure after enteric-coated mycophenolate sodium (EC-MPS) administration. This narrative review examines nine population pharmacokinetic development studies and related limited-sampling and clinical evidence to assess procedures for estimating total plasma MPA area under the concentration–time curve over 12 h (AUC0–12h). Selected three- or four-sample regression and Bayesian procedures support AUC estimation, mainly in adult kidney transplant recipients. Validation against densely sampled noncompartmental AUC assesses agreement with a sampling-based reference; comparison with full-profile AUC from the same model assesses recovery of model-derived exposure from fewer samples. Patient holdout alone does not ensure independent validation of sampling schedules, and sparse low-exposure data limit assessment of underexposure detection. The commonly used 30–60 mg h/L target is supported mainly by mycophenolate mofetil studies in kidney transplantation and requires assay- and indication-specific interpretation. Direct EC-MPS studies support exposure–outcome associations and the feasibility of concentration-guided dosing, while evidence of improved clinical outcomes remains limited. These findings guide selection of candidate monitoring procedures by matching the estimator, sampling schedule, assay and exposure target to the intended population and dosing decision.
Related
- Population pharmacokinetics of piperacillin based on multicenter data to support model-informed precision dosing in critically ill women
- Population pharmacokinetics and model-informed precision dosing of busulfan in Chinese pediatric allogeneic hematopoietic stem cell transplantation: a prospective real-world cohort study
- CSF pharmacokinetics-pharmacodynamics of linezolid in critically brain injured patients, with or without central nervous system healthcare-associated infection. The PK-Pop-LCR Study: A Multicentre Pharmacokinetics and Pharmacodynamics Population Study
- Population pharmacokinetics of vancomycin in patients with liver dysfunction
- Population pharmacokinetics modeling of albendazole and its active metabolite, albendazole sulfoxide in mass drug administration against lymphatic filariasis
BibTeX
@article{yuan2026modelinformed,
title = {{Model-informed AUC-guided monitoring of enteric-coated mycophenolate sodium: population pharmacokinetics and clinical transferability}},
author = {Shixuan Yuan and Tianxue Run and Jingxian Xie and Lu Chen and Dongke Yu and Lijuan Zhang and Yifu Hou},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1897017},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1897017},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Model-informed AUC-guided monitoring of enteric-coated mycophenolate sodium: population pharmacokinetics and clinical transferability
AU - Shixuan Yuan
AU - Tianxue Run
AU - Jingxian Xie
AU - Lu Chen
AU - Dongke Yu
AU - Lijuan Zhang
AU - Yifu Hou
PY - 2026
DA - 2026/11/05
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1897017
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1897017
AB - Delayed, variable absorption and enterohepatic recirculation complicate estimation of mycophenolic acid (MPA) exposure after enteric-coated mycophenolate sodium (EC-MPS) administration. This narrative review examines nine population pharmacokinetic development studies and related limited-sampling and clinical evidence to assess procedures for estimating total plasma MPA area under the concentration–time curve over 12 h (AUC0–12h). Selected three- or four-sample regression and Bayesian procedures support AUC estimation, mainly in adult kidney transplant recipients. Validation against densely sampled noncompartmental AUC assesses agreement with a sampling-based reference; comparison with full-profile AUC from the same model assesses recovery of model-derived exposure from fewer samples. Patient holdout alone does not ensure independent validation of sampling schedules, and sparse low-exposure data limit assessment of underexposure detection. The commonly used 30–60 mg h/L target is supported mainly by mycophenolate mofetil studies in kidney transplantation and requires assay- and indication-specific interpretation. Direct EC-MPS studies support exposure–outcome associations and the feasibility of concentration-guided dosing, while evidence of improved clinical outcomes remains limited. These findings guide selection of candidate monitoring procedures by matching the estimator, sampling schedule, assay and exposure target to the intended population and dosing decision.
SN - 1663-9812
ER -